vaxelis
mcm vaccine b.v. - difterija toxoid, tetanus toxoid, bordetella pertussis antigēnus: klepus toxoid, hemaglutinīna pertaktīna, fimbriae veidi 2 un 3, b hepatīta virsmas antigēnu, kas ražoti rauga šūnām, poliomielīta (inaktivēta): tips 1 (mahoney), tips 2 (mef-1), tips 3 (saukett), kas ražoti vero šūnas/ haemophilus influenzae b tipa polisaharīds (polyribosylribitol fosfāts), kas konjugēts pret meningokoku olbaltumvielu. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vakcīnas - vaxelis (dtap-hb-ipv-hib) ir indicēts pamatskolu un pastiprinātājs vakcinācija zīdaiņiem un maziem bērniem vecumā no 6 nedēļām pret difterija, stingumkrampji, garais klepus, b hepatīts, poliomielīta un invazīvajām slimībām, ko izraisa haemophilus influenzae tips b (hib). vaxel lietošanai jāatbilst oficiālajiem ieteikumiem.
taxofit® augen plus (paziņots 2011.) kapsula
mcm klosterfrau vertriebs gmbh - kapsula
taxofit® a-z energie (paziņots 2011.) tablete
mcm klosterfrau - tablete
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiski līdzekļi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
tecvayli
janssen-cilag international n.v. - teclistamab - multiple mieloma - antineoplastiski līdzekļi - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
enterol 250 mg cietās kapsulas
biocodex, france - saccharomyces boulardii - kapsula, cietā - 250 mg
enterols 250 mg pulveris iekšķīgi lietojamas suspensijas pagatavošanai
biocodex, france - saccharomyces boulardii - pulveris iekšķīgi lietojamas suspensijas pagatavošanai - 250 mg
sapro 50 mg apvalkotās tabletes
sanoswiss uab, lithuania - bikalutamīds - apvalkotā tablete - 50 mg
sapro 150 mg apvalkotās tabletes
sanoswiss uab, lithuania - bikalutamīds - apvalkotā tablete - 150 mg
dutasteride accord 0,5 mg mīkstās kapsulas
accord healthcare b.v., netherlands - dutasterīds - kapsula, mīkstā - 0,5 mg